These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23050928)

  • 21. Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors.
    Hattori Y; Shi L; Ding W; Koga K; Kawano K; Hakoshima M; Maitani Y
    J Control Release; 2009 May; 136(1):30-7. PubMed ID: 19331859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.
    Colbern GT; Dykes DJ; Engbers C; Musterer R; Hiller A; Pegg E; Saville R; Weng S; Luzzio M; Uster P; Amantea M; Working PK
    Clin Cancer Res; 1998 Dec; 4(12):3077-82. PubMed ID: 9865923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.
    Shi C; Cao H; He W; Gao F; Liu Y; Yin L
    Biomed Pharmacother; 2015 Jul; 73():48-57. PubMed ID: 26211582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug interactions with sunitinib.
    Bilbao-Meseguer I; Jose BS; Lopez-Gimenez LR; Gil MA; Serrano L; Castaño M; Sautua S; Basagoiti AD; Belaustegui A; Baza B; Baskaran Z; Bustinza A
    J Oncol Pharm Pract; 2015 Feb; 21(1):52-66. PubMed ID: 24403097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.
    Kang MH; Wang J; Makena MR; Lee JS; Paz N; Hall CP; Song MM; Calderon RI; Cruz RE; Hindle A; Ko W; Fitzgerald JB; Drummond DC; Triche TJ; Reynolds CP
    Clin Cancer Res; 2015 Mar; 21(5):1139-50. PubMed ID: 25733708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors.
    Noble CO; Krauze MT; Drummond DC; Forsayeth J; Hayes ME; Beyer J; Hadaczek P; Berger MS; Kirpotin DB; Bankiewicz KS; Park JW
    Nanomedicine (Lond); 2014 Jul; 9(14):2099-108. PubMed ID: 24494810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modified lactone/carboxylate salt equilibria in vivo by liposomal delivery of 9-nitro-camptothecin.
    Chow DS; Gong L; Wolfe MD; Giovanella BC
    Ann N Y Acad Sci; 2000; 922():164-74. PubMed ID: 11193891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.
    Chen PY; Ozawa T; Drummond DC; Kalra A; Fitzgerald JB; Kirpotin DB; Wei KC; Butowski N; Prados MD; Berger MS; Forsayeth JR; Bankiewicz K; James CD
    Neuro Oncol; 2013 Feb; 15(2):189-97. PubMed ID: 23262509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin.
    Baker JH; Lam J; Kyle AH; Sy J; Oliver T; Co SJ; Dragowska WH; Ramsay E; Anantha M; Ruth TJ; Adam MJ; Yung A; Kozlowski P; Minchinton AI; Ng SS; Bally MB; Yapp DT
    Clin Cancer Res; 2008 Nov; 14(22):7260-71. PubMed ID: 19010842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors.
    Ramsay EC; Anantha M; Zastre J; Meijs M; Zonderhuis J; Strutt D; Webb MS; Waterhouse D; Bally MB
    Clin Cancer Res; 2008 Feb; 14(4):1208-17. PubMed ID: 18281556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanocomposite liposomes containing quantum dots and anticancer drugs for bioimaging and therapeutic delivery: a comparison of cationic, PEGylated and deformable liposomes.
    Wen CJ; Sung CT; Aljuffali IA; Huang YJ; Fang JY
    Nanotechnology; 2013 Aug; 24(32):325101. PubMed ID: 23867977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.
    Verreault M; Strutt D; Masin D; Anantha M; Yung A; Kozlowski P; Waterhouse D; Bally MB; Yapp DT
    BMC Cancer; 2011 Apr; 11():124. PubMed ID: 21477311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention.
    Ramsay E; Alnajim J; Anantha M; Zastre J; Yan H; Webb M; Waterhouse D; Bally M
    Eur J Pharm Biopharm; 2008 Mar; 68(3):607-17. PubMed ID: 17904831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo.
    Tardi PG; Gallagher RC; Johnstone S; Harasym N; Webb M; Bally MB; Mayer LD
    Biochim Biophys Acta; 2007 Mar; 1768(3):678-87. PubMed ID: 17208196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors.
    Levashova Z; Backer M; Hamby CV; Pizzonia J; Backer JM; Blankenberg FG
    J Nucl Med; 2010 Jun; 51(6):959-66. PubMed ID: 20484434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sunitinib inhibits catecholamine synthesis and secretion in pheochromocytoma tumor cells by blocking VEGF receptor 2 via PLC-γ-related pathways.
    Aita Y; Ishii KA; Saito Y; Ikeda T; Kawakami Y; Shimano H; Hara H; Takekoshi K
    Am J Physiol Endocrinol Metab; 2012 Oct; 303(8):E1006-14. PubMed ID: 22912364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma membrane targeting by short chain sphingolipids inserted in liposomes improves anti-tumor activity of mitoxantrone in an orthotopic breast carcinoma xenograft model.
    Cordeiro Pedrosa LR; van Tellingen O; Soullié T; Seynhaeve AL; Eggermont AM; Ten Hagen TL; Verheij M; Koning GA
    Eur J Pharm Biopharm; 2015 Aug; 94():207-19. PubMed ID: 25982691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice.
    Desjardins JP; Abbott EA; Emerson DL; Tomkinson BE; Leray JD; Brown EN; Hamilton M; Dihel L; Ptaszynski M; Bendele RA; Richardson FC
    Anticancer Drugs; 2001 Mar; 12(3):235-45. PubMed ID: 11290871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo.
    Tardi PG; Dos Santos N; Harasym TO; Johnstone SA; Zisman N; Tsang AW; Bermudes DG; Mayer LD
    Mol Cancer Ther; 2009 Aug; 8(8):2266-75. PubMed ID: 19671743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
    Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
    J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.